Abstracts

152 – Proof-of-Concept Trial of VH4524184 (VH-184), a Third-Generation Integrase Strand Transfer Inhibitor

Background New long-acting antiretroviral therapy (ART) regimens are needed to expand treatment choices for people living with HIV-1. VH4524184 (VH-184) is a third-generation integrase strand transfer inhibitor (INSTI) with an enhanced in vitro resistance profile compared with second-generation INSTIs being developed as a long-acting antiretroviral agent for the treatment of HIV-1. Here, we present data…

101 – BACH2-Driven Tissue Resident Memory Programs Promote HIV-1 Persistence

Background Tissue resident memory T cells (TRMs) protect the gut mucosal barrier against microbial invasion by exerting rapid and localized effector functions while restraining excessive inflammation. Yet, pathogens can evade immune clearance and persist. The gut is a major HIV-1 reservoir in people living with HIV-1 (PLWH). However, given the rarity of HIV-1-infected cells (<0.1%) and the…

173 – Brain Gray and White Matter Alterations in Cognitive Long COVID

Background Cognitive dysfunction is a common symptom of Long COVID (LC), but its underlying pathobiology is unclear. We hypothesized that multimodal structural brain MRI imaging in people with cognitive LC (c-LC) would demonstrate grey and white matter alterations in brain regions relevant to c-LC symptoms compared to no LC (n-LC) controls. Methods Individuals with c-LC (new self-reported…

136 – Visualizing the Cell Biology of HIV Latency and Reactivation

Background Studies using the Jurkat T-cell model have identified numerous factors crucial for initiating HIV-1 transcription. However, a significant limitation of transformed cells is their inability to replicate the transitions between active effector cells and quiescent memory T cells, which are the key drivers of HIV latency in vivo.  Methods We use refined primary cell…

144 – T-Cell Responses Induced by GS-1966+GS-1144 Vaccines in Virally Suppressed People With HIV

Background Vaccination to enhance HIV-specific T-cell immunity may be important for HIV cure strategies. GS-1966+GS-1144 is a novel heterologous vaccine regimen comprising GS-1966 (chimpanzee adenovirus vector) and GS-1144 (self-amplifying mRNA-lipid nanoparticle), both encoding a novel conserved HIV-1 immunogen that spans Gag, Pol, and Nef. This regimen was safe and well tolerated in a phase 1b study…

142 – Profiling Therapeutic Vaccine-Driven HIV-Specific CD8 T Cells With Single-Cell TCR Sequencing Assays

Background Generating robust virus-specific CD8+ T cell responses is the major objective of most HIV therapeutic vaccines. However, standard T cell assays fail to distinguish whether vaccine-expanded T cell populations are boosted pre-existing responses and/or newly-recruited clonotypes. Here, we utilized two single cell T cell receptor (TCR) sequencing approaches to characterize CD8+ T cell clonotypes…